CLINICAL_TRIALS
trial_result
· 2009-03-12
Clinical Trial Update: Prevention of Relapse Study of SR58611A in Improved Patients With Generalized Anxiety Disorder [Phase 3]
Summary
A Phase 3 relapse-prevention study of SR58611A in patients with Generalized Anxiety Disorder has been terminated.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Sanofi | Conditions: Anxiety Disorders | Phase 3 | Status: TERMINATED